Drug Trial Radar · NCT05906576
Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease Patients
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 21, 2023
Primary completion
Nov 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Taizhou Mabtech Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Post-marketing registration of Infliximab for injection in Chinese pediatric Crohn's disease patients.
Conditions
- Crohn Disease
Interventions
InfliximabDrug
Infliximab in the treatment of Crohn's disease in children
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical response rate at 14 weeksTime frame: up to 14 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital, Capital Medical University
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.